BioSpace News Archive

BioCapital

ASTHO Commends President Trump’s Commitment to Ending HIV Transmission by 2030

The Association of State and Territorial Health Officials (ASTHO) commends President Trump’s State of the Union pledge to end HIV transmission by 2030.

February 5, 2019
·
2 min read
Business

AARP CEO Jo Ann Jenkins Responds to State of the Union Address

AARP CEO Jo Ann Jenkins released the following statement in response to the State of the Union address

February 5, 2019
·
1 min read
FDA

Bernie Sanders Calls out Catalyst Pharmaceuticals Over Price of LEMS Drug Firdapse

Catalyst won approval in 2018 for the LEMS treatment and set the price of the drug at $375,000 for the rare disease.

February 5, 2019
·
3 min read
·
Alex Keown
Business

In-House Developed Multiple Myeloma Drug Leads the Way for Sanofi

Paris-based Sanofi announced positive results from its pivotal Phase III trial of isatuximab in patients with relapsed/refractory multiple myeloma.

February 5, 2019
·
3 min read
·
Mark Terry
Business

With New CEO MIA, Gilead Reports Tough Q4 and 2018

Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.

February 5, 2019
·
3 min read
·
Mark Terry
Business

Kendall Square Real Estate Costs Could Hit $100 Per Square Foot

According to a real estate analysis, the per-square-foot costs in Kendall Square increased $18 in 2018.

February 5, 2019
·
2 min read
·
Alex Keown
Business

In a Busy Week, Lilly Licenses Tech from Netherlands-Based ProteoNic Biotech

Eli Lilly and Co. has licensed 2G UNic technology from Leiden, the Netherlands-based ProteoNic Biotechnology BV. The tech is used to improve recombinant protein production. No financial details were disclosed.

February 5, 2019
·
2 min read
·
Mark Terry
Business

Genentech Plans Legal Battle to Protect Esbriet from Generic Competition

Genentech, a Roche company, is flexing its litigation muscle this week. The South San Francisco-based company has filed 18 lawsuits over the past few weeks to block competitors from selling a generic version of a treatment for idiopathic pulmonary fibrosis, a fatal lung-scarring disease.

February 5, 2019
·
3 min read
·
Alex Keown
Policy

Pain Therapeutics Criticizes FDA Following Meeting Over Thrice-Rejected Remoxy

Investors are not happy after Austin, Texas-based Pain Therapeutics announced that it was no closer to seeing its drug candidate Remoxy ER, an abuse-deterrent, extended-release gel formulation of oxycodone, approved by the U.S. Food and Drug Administration.

February 5, 2019
·
3 min read
·
Alex Keown